Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation

References

• World Health Organization. Generic medicines: interchangeability of WHO-prequalified generics. WHO Drug Inf. 2016;30(3):370–375.
   Google Scholar
• Cameron A, Mantel-Teeuwisse AK, Leufkens HGM, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15(5):664–673. doi:10.1016/j.jval.2012.04.004
   PubMed Web of Science ®Google Scholar
• Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med. 2015;13:173. doi:10.1186/s12916-015-0415-3
   PubMed Web of Science ®Google Scholar
• Güzel T, Kış M, Şenöz O. The correlation between the left atrial volume index and atrial fibrillation development in heart failure with mildly reduced ejection fraction and long-term follow-up results. Acta Cardiol. 2022;77(7):647–654. doi:10.1080/00015385.2022.2067674
   PubMed Web of Science ®Google Scholar
• Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020;396(10264):1767–1776. doi:10.1016/S0140-6736(20)32439-9
   PubMed Web of Science ®Google Scholar
• Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023. doi:10.1161/CIR.0000000000001193
   Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
   PubMed Web of Science ®Google Scholar
• Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16. doi:10.1007/s40262-013-0100-7
   PubMed Web of Science ®Google Scholar
• Aktan A, Güzel T, Aslan B, et al. Comparison of the real-life clinical outcomes of warfarin with effective time in therapeutic range and non-vitamin K antagonist oral anticoagulants: insight from the AFTER-2 trial. Kardiol Pol. 2023;81(2):132–140. doi:10.33963/KP.a2022.0287
   PubMed Web of Science ®Google Scholar
• Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115–2125. doi:10.1001/jama.2016.16201
   PubMed Web of Science ®Google Scholar
• Decaix T, Kemache K, Gay P, Laprévote O, Ketz F, Pautas É. Prevalence and factors associated with inappropriate dosing of apixaban and rivaroxaban in hospitalized older adults with atrial fibrillation: a cross-sectional study. Drugs Aging. 2023. doi:10.1007/s40266-023-01081-x
   PubMed Web of Science ®Google Scholar
• O’Sullivan ED, Hughes J, Ferenbach DA. Renal aging: causes and consequences. JASN. 2017;28(2):407–420. doi:10.1681/ASN.2015121308
   Web of Science ®Google Scholar
• Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19–28. doi:10.1053/j.ackd.2015.08.004
   PubMed Web of Science ®Google Scholar
• Dent E, Hoogendijk EO, Visvanathan R, Wright ORL. Malnutrition screening and assessment in hospitalised older people: a review. J Nutr Health Aging. 2019;23(5):431–441. doi:10.1007/s12603-019-1176-z
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor. J Clin Pharmacol. 2013;53(3):249–255. doi:10.1002/jcph.5
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• Gue Y, Bloomfield D, Freedholm D, Lip GYH. Comparing the real-world and clinical trial bleeding rates associated with oral anticoagulation treatment for atrial fibrillation. J Clin Med. 2024;13(8):2277. doi:10.3390/jcm13082277
   PubMed Web of Science ®Google Scholar
• Wcy L, Co T, Kkc M, et al. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study. Ann Internal Med. 2022;175(11). doi:10.7326/M22-0511
   Web of Science ®Google Scholar
• Ogilvie IM, Welner SA, Cowell W, Lip GYH. Ischaemic stroke and bleeding rates in “real-world” atrial fibrillation patients. Thromb Haemost. 2011;106(1):34–44. doi:10.1160/TH10-10-0674
   PubMed Web of Science ®Google Scholar
• White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377–399. doi:10.1002/sim.4067
   PubMed Web of Science ®Google Scholar
• Toutenburg H, Rubin DB. Multiple imputation for nonresponse in surveys. Stat Papers. 1990;31(1):180. doi:10.1007/BF02924688
   Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples. Stat Med. 2009;28(25):3083–3107. doi:10.1002/sim.3697
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573–577. doi:10.7326/0003-4819-147-8-200710160-00010
   PubMed Web of Science ®Google Scholar
• Ritchie LA, Harrison SL, Penson PE, et al. Anticoagulation in older people with atrial fibrillation moving to care homes: a data linkage study. Br J Gen Pract. 2023;73(726):e43–e51. doi:10.3399/bjgp.2022.0156
   PubMed Web of Science ®Google Scholar
• Dentali F, Donadini MP, Clark N, et al. Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy. 2011;31(4):386–393. doi:10.1592/phco.31.4.386
   PubMed Web of Science ®Google Scholar
• Desai RJ, Gopalakrishnan C, Dejene S, et al. Comparative outcomes of treatment initiation with brand vs generic warfarin in older patients. Clin Pharma Therap. 2020;107(6):1334–1342. doi:10.1002/cpt.1743
   PubMed Web of Science ®Google Scholar
• Paterson JM, Mamdani M, Juurlink DN, Naglie G, Laupacis A, Stukel TA. Clinical consequences of generic warfarin substitution: an ecological study. JAMA. 2006;296(16):1966–1972. doi:10.1001/jama.296.16.1969-b
   Web of Science ®Google Scholar
• Matsumoto M, Hori M, Tanahashi N, et al. Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial. Hypertens Res. 2014;37(5):457–462. doi:10.1038/hr.2014.1
   PubMed Web of Science ®Google Scholar
• Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138–146. doi:10.1161/CIRCULATIONAHA.113.005008
   PubMed Web of Science ®Google Scholar
• Kato ET, Goto S, Giugliano RP. Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev. 2019;49:115–124. doi:10.1016/j.arr.2018.10.006
   PubMed Web of Science ®Google Scholar